Skip to content
Following the COVID-19 pandemic, the importance of investing in mental healthcare has become more apparent to clinicians, investors, and individuals alike. Psychedelic treatments that target the brain can help in understanding aging-related diseases and developing therapeutics that can treat or prevent devastating diagnoses.

Details

  • Second Stage
Date:
11/04/2022
Start Time:
12:30 pm
End Time:
13:15

Garri Zmudze

Managing Partner at LongeVC, Executive Board Board Member of the Sheba Longevity Center

Garri Zmudze stands at the nexus of biotech and longevity, driving transformative health solutions. As a Managing Partner of LongeVC, advisor to PsyMed Ventures, and an Executive Board Member of the S…

Matias Serebrinsky

General Partner, PsyMed Ventures

Matias is a co-founder and General Partner at PsyMed Ventures, a venture fund focused on frontier mental and brain health technologies, including psychedelic therapeutics. Matias also co-hosts Busines…

Lisa Ireland

Chief Executive Officer, Longevity Science Foundation

Lisa is an accomplished non-profit executive leading global operations for the LSF. Her career spans diverse sectors, including education, healthcare, human services and science. Her previous roles in…

Anastasia Drinevskaya

CEO at Cointelegraph Communications, Cointelegraph

Anastasia Drinevskaya is Creative Director and CEO at Cointelegraph Communications for over 3 years. She is a sought after consultant and speaker for all things blockchain. At Cointelegraph, Anastas…

Dina Burkitbayeva

CEO, PsyMed Ventures, Freedom Biosciences

Dina Burkitbayeva is the co-founder & CEO of Freedom Biosciences, a clinical stage biotech platform developing next generation psychedelic therapeutics. Dina is also the co-founder of PsyMed Ventures,…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now